EA202091930A1 - Макроциклы в качестве модуляторов муковисцидозного трансмембранного регулятора проводимости, их фармацевтические композиции, применение их для лечения муковисцидоза и способ их изготовления - Google Patents
Макроциклы в качестве модуляторов муковисцидозного трансмембранного регулятора проводимости, их фармацевтические композиции, применение их для лечения муковисцидоза и способ их изготовленияInfo
- Publication number
- EA202091930A1 EA202091930A1 EA202091930A EA202091930A EA202091930A1 EA 202091930 A1 EA202091930 A1 EA 202091930A1 EA 202091930 A EA202091930 A EA 202091930A EA 202091930 A EA202091930 A EA 202091930A EA 202091930 A1 EA202091930 A1 EA 202091930A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- manufacture
- pharmaceutical compositions
- fluiscidosis
- fluiscidal
- macrocycles
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000002678 macrocyclic compounds Chemical class 0.000 title 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Abstract
Раскрыты соединения формулы (I)их фармацевтически приемлемые соли, дейтерированные производные любого из вышеперечисленных и метаболиты любого из вышеперечисленных. Также раскрыты содержащие их фармацевтические композиции, способы лечения муковисцидоза с их применением и способы их изготовления.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862631453P | 2018-02-15 | 2018-02-15 | |
PCT/US2019/018042 WO2019161078A1 (en) | 2018-02-15 | 2019-02-14 | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202091930A1 true EA202091930A1 (ru) | 2021-03-12 |
Family
ID=65529899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202091930A EA202091930A1 (ru) | 2018-02-15 | 2019-02-14 | Макроциклы в качестве модуляторов муковисцидозного трансмембранного регулятора проводимости, их фармацевтические композиции, применение их для лечения муковисцидоза и способ их изготовления |
Country Status (37)
Country | Link |
---|---|
US (2) | US11066417B2 (ru) |
EP (2) | EP4198037A1 (ru) |
JP (3) | JP7214743B2 (ru) |
KR (1) | KR102482271B1 (ru) |
CN (2) | CN117285547A (ru) |
AR (1) | AR114254A1 (ru) |
AU (2) | AU2019222758B2 (ru) |
BR (1) | BR112020015509A2 (ru) |
CA (1) | CA3088577A1 (ru) |
CL (1) | CL2020002055A1 (ru) |
CR (1) | CR20200403A (ru) |
DK (1) | DK3752510T3 (ru) |
DO (1) | DOP2023000016A (ru) |
EA (1) | EA202091930A1 (ru) |
EC (1) | ECSP20053845A (ru) |
ES (1) | ES2939775T3 (ru) |
FI (1) | FI3752510T3 (ru) |
GE (1) | GEP20237571B (ru) |
HR (1) | HRP20230030T1 (ru) |
HU (1) | HUE061046T2 (ru) |
IL (2) | IL294042A (ru) |
JO (1) | JOP20200178A1 (ru) |
LT (1) | LT3752510T (ru) |
MA (1) | MA51828B1 (ru) |
MD (1) | MD3752510T2 (ru) |
MX (1) | MX2020008268A (ru) |
PE (1) | PE20210454A1 (ru) |
PL (1) | PL3752510T3 (ru) |
PT (1) | PT3752510T (ru) |
RS (1) | RS64018B1 (ru) |
SG (1) | SG11202006614VA (ru) |
SI (1) | SI3752510T1 (ru) |
TW (2) | TWI828358B (ru) |
UA (1) | UA126304C2 (ru) |
UY (1) | UY38093A (ru) |
WO (1) | WO2019161078A1 (ru) |
ZA (1) | ZA202004357B (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11873300B2 (en) | 2019-08-14 | 2024-01-16 | Vertex Pharmaceuticals Incorporated | Crystalline forms of CFTR modulators |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MD3752510T2 (ro) | 2018-02-15 | 2023-06-30 | Vertex Pharma | Macrociclii ca modulatori ai regulatorului conductanței transmembranare în fibroza chistică, compoziții farmaceutice ale acestora, utilizarea lor în tratamentul fibrozei chistice, și procedeu pentru fabricarea acestora |
FI3880197T3 (fi) * | 2018-11-14 | 2023-05-04 | Vertex Pharma | Menetelmiä kystisen fibroosin hoitamiseksi |
TW202120517A (zh) * | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
TW202115092A (zh) * | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
AU2020328568A1 (en) * | 2019-08-14 | 2022-03-03 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
CN110551077B (zh) * | 2019-09-24 | 2023-01-31 | 新乡市润宇新材料科技有限公司 | 一种光催化分子氧氧化制备n-叔丁基-2-苯并噻唑亚磺酰胺的方法 |
EP4058434A1 (en) * | 2019-11-12 | 2022-09-21 | Genzyme Corporation | 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient cftr activity |
WO2021113809A1 (en) | 2019-12-05 | 2021-06-10 | Genzyme Corporation | Arylamides and methods of use thereof |
WO2021113806A1 (en) | 2019-12-05 | 2021-06-10 | Genzyme Corporation | Arylamides and methods of use thereof |
WO2022194399A1 (en) | 2020-07-13 | 2022-09-22 | Idorsia Pharmaceuticals Ltd | Macrocycles as cftr modulators |
US20230303589A1 (en) | 2020-08-13 | 2023-09-28 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
WO2022076620A1 (en) * | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
AU2021358063A1 (en) * | 2020-10-07 | 2023-05-18 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
PE20231108A1 (es) * | 2020-10-07 | 2023-07-19 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica |
BR112023006470A2 (pt) * | 2020-10-07 | 2023-09-26 | Vertex Pharma | Moduladores de regulador de condutância transmembrana de fibrose cística |
WO2022076621A1 (en) * | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2022076618A1 (en) * | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
EP4225763A1 (en) * | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
AU2021383176A1 (en) * | 2020-11-18 | 2023-06-22 | Vertex Pharmaceuticals Incorporated | Macrocycles containing a 1,3,4-oxadiazole ring for use as modulators of cystic fibrosis transmembrane conductance regulator |
CA3204725A1 (en) | 2020-12-10 | 2022-06-16 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
WO2023150236A1 (en) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol |
WO2023150237A1 (en) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
WO2023154291A1 (en) | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2023196429A1 (en) * | 2022-04-06 | 2023-10-12 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2023224924A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Solid forms of a macrocyclic compounds as cftr modulators and their preparation |
WO2023224931A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
WO2024054840A1 (en) * | 2022-09-07 | 2024-03-14 | Sionna Therapeutics | Macrocyclic compounds, compositions, and methods of using thereof |
WO2024054845A1 (en) * | 2022-09-07 | 2024-03-14 | Sionna Therapeutics | Macrocycic compounds, compositions, and methods of using thereof |
WO2024056779A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Crystalline form of (3s,7s,10r,13r)-13-benzyl-20-fluoro-7-isobutyl-n-(2-(3-methoxy-1,2,4-oxadiazol-5-yl)ethyl)-6,9-dimethyl-1,5,8,11-tetraoxo-10-(2,2,2-trifluoroethyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tetradecahydro-[1]oxa[4,7,10,14]tetraazacycloheptadecino[16,17-f]quinoline-3-carboxamide |
WO2024056791A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators |
WO2024056798A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
CN115536493A (zh) * | 2022-10-20 | 2022-12-30 | 海门瑞一医药科技有限公司 | 一种制取3,3,3-三氟甲基-2,2-二甲基丙烷醇的简单方法 |
Family Cites Families (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2677682A (en) | 1951-08-24 | 1954-05-04 | American Cyanamid Co | Sulfonamido pteridines |
ID18983A (id) | 1996-12-04 | 1998-05-28 | Lilly Co Eli | Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia |
SE0001899D0 (sv) | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
ES2234451T1 (es) | 2001-11-14 | 2005-07-01 | Teva Pharmaceutical Industries Ltd. | Formas cristalinas y amorfas de losartan potasio y procedimiento para su preparacion. |
CN1925854A (zh) | 2003-11-14 | 2007-03-07 | 沃泰克斯药物股份有限公司 | 可用作atp-结合弹夹转运蛋白调控剂的噻唑和噁唑 |
JP4960708B2 (ja) | 2004-01-30 | 2012-06-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atp結合カセットトランスポーターのモジュレーター |
US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
ME02970B (me) | 2004-06-24 | 2018-07-20 | Vertex Pharma | Modulatori atp-vezujućih kasetnih transportera |
RU2008109031A (ru) | 2005-08-11 | 2009-09-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Модуляторы муковисцидозного трансмембранного регулятора проводимости |
WO2007053641A2 (en) | 2005-11-01 | 2007-05-10 | Mars, Incorporated | A-type procyanidins and inflammation |
CA2635214A1 (en) | 2005-12-27 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Compounds useful in cftr assays and methods therewith |
NZ569327A (en) | 2005-12-28 | 2011-09-30 | Vertex Pharma | 1-(benzo [d] [1,3] dioxol-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-binding cassette transporters for the treatment of cystic fibrosis |
LT1993360T (lt) | 2005-12-28 | 2017-06-12 | Vertex Pharmaceuticals Incorporated | N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma |
US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
DK3091011T3 (en) | 2006-04-07 | 2018-02-26 | Vertex Pharma | MODULATORS OF ATP BINDING CASSETTE TRANSPORT |
WO2007134279A2 (en) | 2006-05-12 | 2007-11-22 | Vertex Pharmaceuticals Incorporated | Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
AU2007351454B2 (en) | 2006-11-03 | 2013-07-18 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
BRPI0811065A2 (pt) | 2007-06-08 | 2014-12-02 | Abbott Lab | Indazóis 5-heteroaril substituídos como inibidores de quinase |
AU2008301907B2 (en) | 2007-09-14 | 2014-02-20 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
KR20100101130A (ko) | 2007-12-07 | 2010-09-16 | 버텍스 파마슈티칼스 인코포레이티드 | 3-(6-(1-(2,2-디플루오로벤조[d][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태 |
CA2707494C (en) | 2007-12-07 | 2018-04-24 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
NZ602030A (en) | 2008-02-28 | 2014-02-28 | Vertex Pharma | Heteroaryl derivatives as cftr modulators |
JP5575768B2 (ja) | 2008-08-13 | 2014-08-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | 薬学的組成物およびその投与 |
MX2011003249A (es) | 2008-09-29 | 2011-05-19 | Vertex Pharma | Unidades de dosificacion del acido 3-(6-(1-(2,2-difluorobenzo[d][1 ,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoi co. |
AU2009308284B2 (en) * | 2008-10-23 | 2016-02-04 | Vertex Pharmaceuticals, Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
UA104876C2 (ru) | 2008-11-06 | 2014-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Модуляторы атф-связывающих кассетных транспортеров |
DK2365972T3 (en) | 2008-11-06 | 2015-01-19 | Vertex Pharma | Modulators of atp-binding cassette conveyors |
EP2821400B1 (en) | 2009-03-20 | 2017-09-27 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
AU2010310449A1 (en) | 2009-10-22 | 2012-05-03 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
CA2792207A1 (en) | 2010-03-19 | 2011-09-22 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
PL3835297T3 (pl) | 2010-03-25 | 2023-09-11 | Vertex Pharmaceuticals Incorporated | Synteza i związki pośrednie (r)-1-(2,2-difluorobenzo[d][1,3]-dioksol-5-ilo)-n-(1-(2,3-dihydroksypropylo)-6-fluoro-2-(1-hydroksy-2-metylopropan-2-ylo)-1h-indol-5-ilo)-cyklopropanokarboksyamidu |
LT3150198T (lt) | 2010-04-07 | 2021-12-10 | Vertex Pharmaceuticals Incorporated | 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas |
RU2579370C2 (ru) | 2010-04-07 | 2016-04-10 | Вертекс Фармасьютикалз Инкорпорейтед | Твердые формы 3-(2, 2-дифторбензо[d][1, 3] диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты |
EP2560649A1 (en) | 2010-04-22 | 2013-02-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
SG184987A1 (en) | 2010-04-22 | 2012-11-29 | Vertex Pharma | Process of producing cycloalkylcarboxamido-indole compounds |
US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
CN103153287A (zh) | 2010-08-23 | 2013-06-12 | 弗特克斯药品有限公司 | (R)-1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)-N-(1-(2,3-二羟基丙基)-6-氟-2-(1-羟基-2-甲基丙-2-基)-1H-吲哚-5-基)环丙烷甲酰胺的药物组合物及其施用 |
EP2608775A2 (en) | 2010-08-27 | 2013-07-03 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
WO2013038386A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Heterocyclic compounds for the treatment of cystic fibrosis |
BR112014010368A2 (pt) | 2011-10-31 | 2017-04-25 | Xenon Pharmaceuticals Inc | biaril éter sulfonamidas e seu uso como agentes terapêuticos |
WO2013070961A1 (en) | 2011-11-08 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
RU2644723C2 (ru) | 2012-01-25 | 2018-02-13 | Вертекс Фармасьютикалз Инкорпорейтед | Препараты 3-(6-(1-(2, 2-дифторбензо[d][1, 3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты |
WO2013130669A1 (en) | 2012-02-27 | 2013-09-06 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administration thereof |
WO2013158121A1 (en) | 2012-04-20 | 2013-10-24 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
GB201207406D0 (en) | 2012-04-27 | 2012-06-13 | Glaxo Group Ltd | Novel compounds |
MX2014014234A (es) | 2012-05-22 | 2015-05-07 | Genentech Inc | Benzamidas n-sustituidas y su uso en el tratamiento del dolor. |
EP2858645A1 (en) | 2012-06-08 | 2015-04-15 | Vertex Pharmaceuticals Incorporated | Pharmaceuticl compositions for the treatment of cftr -mediated disorders |
AU2013290444B2 (en) | 2012-07-16 | 2018-04-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof |
CN103571906B (zh) | 2012-07-27 | 2018-12-11 | 上海泽元海洋生物技术有限公司 | 一种利用微藻高效生产虾青素的新方法 |
IL283276B1 (en) | 2012-11-02 | 2024-01-01 | Vertex Pharma | Preparations containing 3-(6-(1-(2,2-difluorobenzo[1,3][D]dioxol-5-yl)cycloproponecarboxamide)-3-methylpyridin-2-yl)benzoic acid and N-(5-hydroxy- 2,4-ditert-butyl-phenyl)-4-oxo-H1-quinoline-3-carboxamide and their uses |
MY183582A (en) | 2012-11-19 | 2021-02-26 | Vertex Pharmaceuticals Europe Ltd | Deuterated cftr potentiators |
US9663508B2 (en) | 2013-10-01 | 2017-05-30 | Amgen Inc. | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors |
PT3068392T (pt) | 2013-11-12 | 2021-05-14 | Vertex Pharma | Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por condutância transmembrana da fibrose quística (cftr) |
PL3925607T3 (pl) | 2014-04-15 | 2023-10-30 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa |
CN112250627B (zh) | 2014-10-06 | 2024-02-02 | 弗特克斯药品有限公司 | 囊性纤维化跨膜转导调节因子调节剂 |
AU2015330923B2 (en) | 2014-10-07 | 2020-03-12 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
HUE055423T2 (hu) | 2014-11-18 | 2021-11-29 | Vertex Pharma | Eljárás nagy áteresztõképességû tesztelõ nagy teljesítményû folyadék-kromatográfia elvégzésére |
US10196384B2 (en) | 2015-03-31 | 2019-02-05 | Vertex Pharmaceuticals (Europe) Limited | Deuterated CFTR modulators |
CN108367002A (zh) | 2015-09-21 | 2018-08-03 | 弗特克斯药品欧洲有限公司 | 氘化cftr增强剂的给予 |
EP3854782A1 (en) | 2016-03-30 | 2021-07-28 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
ES2946970T3 (es) | 2016-03-31 | 2023-07-28 | Vertex Pharma | Regulador de conductancia transmembrana de moduladores de fibrosis quística |
BR112018070747B1 (pt) | 2016-04-07 | 2024-01-09 | Proteostasis Therapeutics, Inc | Átomos de silicone contendo análogos de ivacaftor, composições farmacêuticas e usos terapêuticos |
EP3448842A1 (en) | 2016-04-26 | 2019-03-06 | AbbVie S.À.R.L. | Modulators of cystic fibrosis transmembrane conductance regulator protein |
US10138227B2 (en) | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
ES2954658T3 (es) | 2016-06-21 | 2023-11-23 | Proteostasis Therapeutics Inc | Compuestos, composiciones y procedimientos para aumentar la actividad de CFTR |
EP3519401B1 (en) | 2016-09-30 | 2021-09-29 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
US9981910B2 (en) | 2016-10-07 | 2018-05-29 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
US10399940B2 (en) | 2016-10-07 | 2019-09-03 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
US20190248765A1 (en) | 2016-10-26 | 2019-08-15 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
WO2018081377A1 (en) | 2016-10-26 | 2018-05-03 | Proteostasis Therapeutics, Inc. | N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis |
CA3041811A1 (en) | 2016-10-26 | 2018-05-03 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for modulating cftr |
WO2018080591A1 (en) | 2016-10-27 | 2018-05-03 | Vertex Pharmaceuticals (Europe) Limited | Methods of treatment with deuterated cftr potentiators |
MX2019005822A (es) | 2016-11-18 | 2019-09-09 | Cystic Fibrosis Found Therapeutics Inc | Pirrolopirimidinas como potenciadores de cftr. |
IL277491B (en) | 2016-12-09 | 2022-08-01 | Vertex Pharma | Modulatory modulation of transmembrane conductance in cystic fibrosis, pharmaceutical preparations, treatment methods, and a process for creating the modulator |
BR112019012335A2 (pt) | 2016-12-16 | 2020-03-03 | Cystic Fibrosis Foundation Therapeutics, Inc. | Derivados de heteroarila bicíclica como potenciadores de cftr |
EP3558982A1 (en) | 2016-12-20 | 2019-10-30 | AbbVie S.À.R.L. | Deuterated cftr modulators and methods of use |
CN110177788B (zh) | 2017-01-07 | 2023-03-24 | 重庆复创医药研究有限公司 | 作为bcl-2选择性凋亡诱导剂的化合物 |
TW201831471A (zh) | 2017-02-24 | 2018-09-01 | 盧森堡商艾伯維公司 | 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法 |
US20180280349A1 (en) | 2017-03-28 | 2018-10-04 | Vertex Pharmaceuticals Incorporated | Methods of treating cystic fibrosis in patients with residual function mutations |
PE20200008A1 (es) | 2017-03-30 | 2020-01-06 | Hoffmann La Roche | Isoquinolinas como inhibidores de hpk1 |
CA3061476A1 (en) | 2017-04-28 | 2018-11-01 | Proteostasis Therapeutics, Inc. | 4-sulfonylaminocarbonylquinoline derivatives for increasing cftr activity |
EP3634402A1 (en) | 2017-06-08 | 2020-04-15 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
CA3068609A1 (en) | 2017-07-01 | 2019-01-10 | Vertex Pharmaceuticals Incorporated | Compositions and methods for treatment of cystic fibrosis |
SG11202000230VA (en) | 2017-07-11 | 2020-02-27 | Vertex Pharma | Carboxamides as modulators of sodium channels |
AU2018304168B2 (en) | 2017-07-17 | 2023-05-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
US20200171015A1 (en) | 2017-07-17 | 2020-06-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
EP3662079A4 (en) | 2017-07-31 | 2021-04-14 | Technion Research & Development Foundation Limited | METHODS OF DETECTION OF MODIFIED AND NON-MODIFIED DNA |
CN111051280B (zh) | 2017-08-02 | 2023-12-22 | 弗特克斯药品有限公司 | 制备吡咯烷化合物的方法 |
US10988454B2 (en) | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
US20210369749A1 (en) | 2017-10-06 | 2021-12-02 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
US10654829B2 (en) | 2017-10-19 | 2020-05-19 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
US20210228489A1 (en) | 2017-12-04 | 2021-07-29 | Vertex Pharmaceuticals Incorporated | Compositions for treating cystic fibrosis |
MX2020005753A (es) | 2017-12-08 | 2020-08-20 | Vertex Pharma | Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica. |
TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
MD3752510T2 (ro) | 2018-02-15 | 2023-06-30 | Vertex Pharma | Macrociclii ca modulatori ai regulatorului conductanței transmembranare în fibroza chistică, compoziții farmaceutice ale acestora, utilizarea lor în tratamentul fibrozei chistice, și procedeu pentru fabricarea acestora |
WO2019191620A1 (en) | 2018-03-30 | 2019-10-03 | Vertex Pharmaceuticals Incorporated | Crystalline forms of modulators of cftr |
EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
FI3880197T3 (fi) | 2018-11-14 | 2023-05-04 | Vertex Pharma | Menetelmiä kystisen fibroosin hoitamiseksi |
BR112021011643A2 (pt) | 2018-12-21 | 2021-09-08 | Novartis Ag | Compostos macrocíclicos e seu uso no tratamento de doença |
WO2020161623A1 (en) | 2019-02-06 | 2020-08-13 | Novartis Ag | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease |
WO2020191227A1 (en) | 2019-03-20 | 2020-09-24 | Cornell University | Methods for controlling prostaglandin-mediated biological processes |
UY38630A (es) | 2019-04-03 | 2020-10-30 | Vertex Pharma | Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
WO2020214921A1 (en) | 2019-04-17 | 2020-10-22 | Vertex Pharmaceuticals Incorporated | Solid forms of modulators of cftr |
WO2020242935A1 (en) | 2019-05-29 | 2020-12-03 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
TW202115092A (zh) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
AU2020328568A1 (en) | 2019-08-14 | 2022-03-03 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
BR112022002605A2 (pt) | 2019-08-14 | 2022-05-03 | Vertex Pharma | Formas cristalinas de moduladores de cftr |
TW202120517A (zh) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
EP4058434A1 (en) | 2019-11-12 | 2022-09-21 | Genzyme Corporation | 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient cftr activity |
CN115003659A (zh) | 2019-11-12 | 2022-09-02 | 健赞公司 | 用于治疗由cftr活性缺乏介导的疾患的5元杂芳基氨基磺酰胺 |
CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
US20230303589A1 (en) | 2020-08-13 | 2023-09-28 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
-
2019
- 2019-02-14 MD MDE20201268T patent/MD3752510T2/ro unknown
- 2019-02-14 EA EA202091930A patent/EA202091930A1/ru unknown
- 2019-02-14 HR HRP20230030TT patent/HRP20230030T1/hr unknown
- 2019-02-14 KR KR1020207026102A patent/KR102482271B1/ko active IP Right Grant
- 2019-02-14 EP EP22209444.3A patent/EP4198037A1/en active Pending
- 2019-02-14 UA UAA202005844A patent/UA126304C2/uk unknown
- 2019-02-14 PL PL19707648.2T patent/PL3752510T3/pl unknown
- 2019-02-14 IL IL294042A patent/IL294042A/en unknown
- 2019-02-14 FI FIEP19707648.2T patent/FI3752510T3/fi active
- 2019-02-14 AR ARP190100372A patent/AR114254A1/es unknown
- 2019-02-14 IL IL276662A patent/IL276662B/en unknown
- 2019-02-14 CN CN202310999824.3A patent/CN117285547A/zh active Pending
- 2019-02-14 JO JOP/2020/0178A patent/JOP20200178A1/ar unknown
- 2019-02-14 CR CR20200403A patent/CR20200403A/es unknown
- 2019-02-14 ES ES19707648T patent/ES2939775T3/es active Active
- 2019-02-14 SI SI201930446T patent/SI3752510T1/sl unknown
- 2019-02-14 HU HUE19707648A patent/HUE061046T2/hu unknown
- 2019-02-14 CN CN201980025942.6A patent/CN112004817B/zh active Active
- 2019-02-14 MX MX2020008268A patent/MX2020008268A/es unknown
- 2019-02-14 JP JP2020543326A patent/JP7214743B2/ja active Active
- 2019-02-14 PE PE2020001222A patent/PE20210454A1/es unknown
- 2019-02-14 DK DK19707648.2T patent/DK3752510T3/da active
- 2019-02-14 PT PT197076482T patent/PT3752510T/pt unknown
- 2019-02-14 CA CA3088577A patent/CA3088577A1/en active Pending
- 2019-02-14 RS RS20230079A patent/RS64018B1/sr unknown
- 2019-02-14 WO PCT/US2019/018042 patent/WO2019161078A1/en active Application Filing
- 2019-02-14 LT LTEPPCT/US2019/018042T patent/LT3752510T/lt unknown
- 2019-02-14 BR BR112020015509-8A patent/BR112020015509A2/pt unknown
- 2019-02-14 AU AU2019222758A patent/AU2019222758B2/en active Active
- 2019-02-14 EP EP19707648.2A patent/EP3752510B1/en active Active
- 2019-02-14 US US16/276,350 patent/US11066417B2/en active Active
- 2019-02-14 GE GEAP201915439A patent/GEP20237571B/en unknown
- 2019-02-14 SG SG11202006614VA patent/SG11202006614VA/en unknown
- 2019-02-14 MA MA51828A patent/MA51828B1/fr unknown
- 2019-02-15 UY UY38093A patent/UY38093A/es unknown
- 2019-02-15 TW TW111138279A patent/TWI828358B/zh active
- 2019-02-15 TW TW108105209A patent/TWI780304B/zh active
-
2020
- 2020-07-15 ZA ZA2020/04357A patent/ZA202004357B/en unknown
- 2020-08-07 CL CL2020002055A patent/CL2020002055A1/es unknown
- 2020-09-04 EC ECSENADI202053845A patent/ECSP20053845A/es unknown
-
2021
- 2021-05-18 US US17/323,267 patent/US11866450B2/en active Active
-
2022
- 2022-06-23 JP JP2022100979A patent/JP2022126802A/ja not_active Withdrawn
- 2022-09-15 AU AU2022231721A patent/AU2022231721A1/en active Pending
-
2023
- 2023-01-27 DO DO2023000016A patent/DOP2023000016A/es unknown
-
2024
- 2024-02-05 JP JP2024015975A patent/JP2024050811A/ja active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11873300B2 (en) | 2019-08-14 | 2024-01-16 | Vertex Pharmaceuticals Incorporated | Crystalline forms of CFTR modulators |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202091930A1 (ru) | Макроциклы в качестве модуляторов муковисцидозного трансмембранного регулятора проводимости, их фармацевтические композиции, применение их для лечения муковисцидоза и способ их изготовления | |
EA201991403A1 (ru) | Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора | |
TN2019000079A1 (en) | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | |
EA202192704A1 (ru) | Средства, модулирующие регулятор трансмембранной проводимости при муковисцидозе | |
NZ730794A (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
MX2020002806A (es) | Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso. | |
TN2018000175A1 (en) | Indane derivatives as mglur7 modulators | |
EA201990850A1 (ru) | Модулятор муковисцидозного трансмембранного регулятора проводимости, фармацевтические композиции, способы лечения и способы получения модулятора | |
CR20190211A (es) | Modulador del regulador de conductancia de transmembrana de fibrosis quistica, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador | |
NZ754805B2 (en) | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | |
EA201992719A1 (ru) | Дейтерированные пиридонамиды и их пролекарства в качестве модуляторов натриевых каналов |